BACKGROUND: Cancer survivors are at risk of developing a second primary cancer (SPC) later in life because of persisting effects of genetic and behavioural risk factors, the long-term sequelae of chemotherapy, radiotherapy and the passage of time. This is the first study with Austrian data on an array of entities, estimating the risk of SPCs in a population-based study by calculating standardized incidence ratios (SIRs).METHODS: This retrospective cohort study included all invasive incident cancer cases diagnosed within the years 1988 to 2005 being registered in the Tyrol and Vorarlberg Cancer Registries. Person years at risk (PYAR) were calculated from time of first diagnosis plus 2\ua0months until the exit date, defined as the date of dia...
PURPOSE:Longitudinal studies are needed to characterise the burden of second primary malignancies am...
BackgroundIn the current study, the authors attempted to describe the incidence, most common sites, ...
Testicular cancer survival rates improved dramatically after cisplatin-based therapy was introduced ...
Abstract Background Cancer survivors are at risk of developing a second primary cancer (SPC) later i...
This study aims to investigate the relative risk of SPCs in cancer survivors in Switzerland combinin...
Background More people than ever before are currently living with a diagnosis of cancer and the n...
More people than ever before are currently living with a diagnosis of cancer and the number of peopl...
International audienceBACKGROUND: Although cancer survivors are known to be at greater risk of devel...
Longitudinal studies are needed to characterise the burden of second primary malignancies among canc...
International audienceBackgroundTo develop a prediction model to quantify the cumulative risk of Sec...
Background Cancer survivors face an increased likelihood of being subsequently diagnosed with anothe...
Background Cancer survivors face an increased likelihood of being subsequently diagnosed with anothe...
BACKGROUND: In high-quality cancer registration systems, about one in eight incident cancers are sec...
We aimed at investigating the distribution and risk of all second discordant primary cancers (SDPCs)...
Background: The authors' systematic review indicated an increasing trend in the risk of second prima...
PURPOSE:Longitudinal studies are needed to characterise the burden of second primary malignancies am...
BackgroundIn the current study, the authors attempted to describe the incidence, most common sites, ...
Testicular cancer survival rates improved dramatically after cisplatin-based therapy was introduced ...
Abstract Background Cancer survivors are at risk of developing a second primary cancer (SPC) later i...
This study aims to investigate the relative risk of SPCs in cancer survivors in Switzerland combinin...
Background More people than ever before are currently living with a diagnosis of cancer and the n...
More people than ever before are currently living with a diagnosis of cancer and the number of peopl...
International audienceBACKGROUND: Although cancer survivors are known to be at greater risk of devel...
Longitudinal studies are needed to characterise the burden of second primary malignancies among canc...
International audienceBackgroundTo develop a prediction model to quantify the cumulative risk of Sec...
Background Cancer survivors face an increased likelihood of being subsequently diagnosed with anothe...
Background Cancer survivors face an increased likelihood of being subsequently diagnosed with anothe...
BACKGROUND: In high-quality cancer registration systems, about one in eight incident cancers are sec...
We aimed at investigating the distribution and risk of all second discordant primary cancers (SDPCs)...
Background: The authors' systematic review indicated an increasing trend in the risk of second prima...
PURPOSE:Longitudinal studies are needed to characterise the burden of second primary malignancies am...
BackgroundIn the current study, the authors attempted to describe the incidence, most common sites, ...
Testicular cancer survival rates improved dramatically after cisplatin-based therapy was introduced ...